Report from a consensus meeting: Response to chemoradiotherapy in rectal cancer - predictor of cure and a crucial new choice for the patient: On behalf of the Champalimaud 2014 Faculty for 'Rectal cancer: When NOT to operate'

Colorectal Disease

Volumn 16, Issue 5, 2014, Pages 334-337

  Heald, Richard John ^a   Beets, Geerard ^b   Carvalho, Carlos ^c  

^a PELICAN CANCER FOUNDATION   (United Kingdom)

^b CHAMPALIMAUD FOUNDATION   (Portugal)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESEARCH; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMORBIDITY; CONSENSUS; DISEASE FREE SURVIVAL; FOLLOW UP; HISTOPATHOLOGY; HONESTY; HUMAN; MEDICAL HISTORY; METASTASIS; MINIMAL RESIDUAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PREOPERATIVE TREATMENT; PRIMARY TUMOR; PRIORITY JOURNAL; RECTUM CANCER; SURGICAL RISK; TREATMENT RESPONSE; CONSENSUS DEVELOPMENT; RECTAL NEOPLASMS; TREATMENT OUTCOME; WATCHFUL WAITING;

CHEMORADIOTHERAPY; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; HUMANS; RECTAL NEOPLASMS; TREATMENT OUTCOME; WATCHFUL WAITING;

EID: 84898450140     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/codi.12627     Document Type: Article

References (28)

1. Habr-Gama A, Sabbaga J, Gama-Rodrigues J et al. Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management? Dis Colon Rectum 2013; 56: 1109-17.
2. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352: 476-87.
3. Yu SK, Tait D, Chau I, Brown G. MRI predictive factors for tumor response in rectal cancer following neoadjuvant chemoradiation therapy-implications for induction chemotherapy? Int J Radiat Oncol Biol Phys 2013; 87: 505-11.
4. Smith JD, Ruby JA, Goodman KA et al. Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy. Ann Surg 2012; 256: 965-72.
5. Taylor FG, Quirke P, Heald RJ et al. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study. Ann Surg 2011; 253: 711-9.
6. Chua YJ, Barbachano Y, Cunningham D et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol 2010; 11: 241-8.
7. Beets G. Watch and Wait Maastricht experience. Presentation at Rectal cancer: When Not to Operate. Lisbon: 2014.
8. Patel UB, Taylor F, Blomqvist L et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol 2011; 29: 3753-60.
9. Habr-Gama A, Perez RO, Proscurshim I et al. Interval between surgery and neoadjuvant chemoradiation therapy for distal rectal cancer: does delayed surgery have an impact on outcome? Int J Radiat Oncol Biol Phys 2008; 71: 1181-8.
10. Wolthuis AM, Penninckx F, Haustermans K et al. Impact of interval between neoadjuvant chemoradiotherapy and TME for locally advanced rectal cancer on pathologic response and oncologic outcome. Ann Surg Oncol 2012; 19: 2833-41.
11. Garcia-Aguilar J, Smith DD, Avila K, Bergsland EK, Chu P, Krieg RM. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg 2011; 254: 97-102.
12. Evans J, Tait D, Swift I et al. Timing of surgery following preoperative therapy in rectal cancer: the need for a prospective randomized trial? Dis Colon Rectum 2011; 54: 1251-9.
13. Sloothaak DA, Geijsen DE, van Leersum NJ et al. Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg 2013; 100: 933-9.
14. Kerr SF, Norton S, Glynne-Jones R. Delaying surgery after neoadjuvant chemoradiotherapy for rectal cancer may reduce postoperative morbidity without compromising prognosis. Br J Surg 2008; 95: 1534-40.
15. Tulchinsky H, Shmueli E, Figer A, Klausner JM, Rabau M. An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer. Ann Surg Oncol 2008; 15: 2661-7.
16. Pettersson D, Holm T, Iversen H, Blomqvist L, Glimelius B, Martling A. Preoperative short-course radiotherapy with delayed surgery primary rectal cancer. Br J Surg 2012; 99: 577-83.
17. Francois Y et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 1999; 17: 2396.
18. Nilsson PJ, van Etten B, Hospers GA, et al. Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer-the RAPIDO trial. BMC Cancer 2013; 13: 279.
19. Gerard JP et al. Improved sphincter preservation in low rectal cancer with high-dose preoperative radiotherapy: the lyon R96-02 randomized trial. J Clin Oncol 2004; 22: 2404-9.
20. Mirnezami A, Mirnezami R, Chandrakumaran K, Sasapu K, Sagar P, Finan P. Increased local recurrence and reduced survival from colorectal cancer following anastomotic leak: systematic review and meta-analysis. Ann Surg 2011; 253: 890-9.
21. den Dulk M, Marijnen CAM, Collette L et al. Multicentre analysis of oncological and survival outcomes following anastomotic leakage after rectal cancer surgery. Br J Surg 2009; 96: 1066-75.
22. Manceau G, Karoui M, Werner A, Mortensen NJ, Hannoun L. Comparative outcomes of rectal cancer surgery between elderly and non-elderly patients: a systematic review. Lancet Oncol 2012; 13: e525-36.
23. Brouquet A, Mortenson MM, Vauthey JN et al. Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy? J Am Coll Surg 2010; 210: 934-41.
24. Tyc-Szczepaniak D, Wyrwicz L, Kepka L et al. Palliative radiotherapy and chemotherapy instead of surgery in symptomatic rectal cancer with synchronous unresectable metastases: a phase II study. Ann Oncol 2013; 24: 2829-34.
25. Poultsides GA, Servais EL, Saltz LB et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 2009; 27: 3379-84.
26. Habr-Gama A, Gama-Rodrigues J, Sao Juliao GP et al. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int J Rad Oncol Biol Phys 2014; 88: 822-8.
27. Habr-Gama A, Perez RO, Wynn G, Marks J, Kessler H, Gama-Rodrigues J. Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. Dis Colon Rectum 2010; 53: 1692-8.
28. Weeks JC, Catalano PJ, Cronin A et al. Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med 2012; 367: 1616-25.